Edwards Lifesciences

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell EW and other ETFs, options, and stocks.

About EW

Edwards Lifesciences Corp. engages in patient-focused medical innovations for heart disease and critical care monitoring. Its products are categorized into four main areas: Transcatheter Aortic Valve Replacement, Transcatheter Mitral and Tricuspid Therapies, Surgical Structural Heart, and Critical Care. 

CEO
Bernard J. Zovighian
CEOBernard J. Zovighian
Employees
15,800
Employees15,800
Headquarters
Irvine, California
HeadquartersIrvine, California
Founded
1958
Founded1958
Employees
15,800
Employees15,800

EW Key Statistics

Market cap
44.55B
Market cap44.55B
Price-Earnings ratio
32.69
Price-Earnings ratio32.69
Dividend yield
Dividend yield
Average volume
4.58M
Average volume4.58M
High today
High today
Low today
Low today
Open price
$78.21
Open price$78.21
Volume
0.00
Volume0.00
52 Week high
$87.89
52 Week high$87.89
52 Week low
$65.94
52 Week low$65.94

Stock Snapshot

The current Edwards Lifesciences(EW) stock price is $78.00, with a market capitalization of 44.55B. The stock trades at a price-to-earnings (P/E) ratio of 32.69.

During the trading day, Edwards Lifesciences(EW) stock saw an opening price of $78.21, a peak of —, and a bottom of —.

Trading volume for Edwards Lifesciences(EW) stock has reached 0, versus its average volume of 4.58M.

Over the past 52 weeks, Edwards Lifesciences(EW) stock has traded between a high of $87.89 and a low of $65.94.

Over the past 52 weeks, Edwards Lifesciences(EW) stock has traded between a high of $87.89 and a low of $65.94.

EW News

Simply Wall St 1h
Assessing Edwards Lifesciences Valuation Ahead Of Its Q4 2025 Earnings Release

Edwards Lifesciences (EW) enters a key week for shareholders, with its Q4 2025 earnings release and earnings call scheduled for February 10, 2026, after market...

Assessing Edwards Lifesciences Valuation Ahead Of Its Q4 2025 Earnings Release
Nasdaq 3h
Edwards Lifesciences Q4 25 Earnings Conference Call At 5:00 PM ET

(RTTNews) - Edwards Lifesciences Corp. (EW) will host a conference call at 5:00 PM ET on February 10, 2026, to discuss Q4 25 earnings results. To access the li...

Edwards Lifesciences Q4 25 Earnings Conference Call At 5:00 PM ET
Nasdaq 5d
Edwards Lifesciences Shares Cross Below 200 DMA

In trading on Wednesday, shares of Edwards Lifesciences Corp (Symbol: EW) crossed below their 200 day moving average of $115.23, changing hands as low as $110.5...

Edwards Lifesciences Shares Cross Below 200 DMA

Analyst ratings

69%

of 35 ratings
Buy
68.6%
Hold
31.4%
Sell
0%

More EW News

TipRanks 6d
Edwards Lifesciences price target lowered to $94 from $95 at UBS

UBS analyst Danielle Antalffy lowered the firm’s price target on Edwards Lifesciences (EW) to $94 from $95 and keeps a Neutral rating on the shares. Published...

Simply Wall St 7d
How Edwards’ TAVR-First Pivot And JenaValve Exit At Edwards Lifesciences Has Changed Its Investment Story

In recent weeks, Edwards Lifesciences has drawn attention after exiting its planned JenaValve acquisition, raising 2026 EPS guidance, and emphasizing growth in...

How Edwards’ TAVR-First Pivot And JenaValve Exit At Edwards Lifesciences Has Changed Its Investment Story

People also own

Based on the portfolios of people who own EW. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.